IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	Art Unit:
	)	
LUND, et al.	)	Examiner:
	)	
Serial No.: Not yet assigned	)	Washington, D.C.
	)	
Filed: even date herewith	)	November 29, 2001
	)	
For: INHIBITION OF INVASIVE REMODELLING	)	Docket No.: LUND=1A

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, D.C. 20231

S i r :

IN THE SPECIFICATION

On page 1, immediately after the title, insert the following new paragraphs:

This is a continuation of Serial No. 09/319,464 filed August 27, 1999, which is the national stage under 35 U.S.C. 371 of PCT/DK97/00555, filed December 8, 1997, and published in English. The latter application claims §119 priority from DK 1402/96, filed December 6, 1996.

The prior application(s) set forth above are hereby incorporated by reference in their entirety.

Please replace the paragraph beginning at page 25, line 27, with the following rewritten paragraph:

Preferred examples of the at least one second substance are tissue inhibitor of metalloproteases (such as TIMP-1, TIMP-2, and TIMP-3), alpha-2-macroglobulin, Galardin™, -[2R-2-(hydroxamidocarbonylmethyl)-4-methylpentanolyl]-L-tryptophan methylamide, batimastat, marimastat, Gl 129471, Gl 168, Gl 173, Gl 179, Gl 184, Cl-A, Cl-B, RP59794, SC-44463, Ro31-4724, CT1746, SCH 47890, a peptide hydroxamate (such as Pro-Leu-Gly-NHOH), LMHKPRCGVPDVGG (SEQ ID NO:1), TNF-α releasing protease inhibitor, Zincov®, Pro-Ileu, phosphoramidon, thiorphan, tiopronin, a tetracycline, N-acetylcysteine, EDTA, or 1,10 phenanthrolene, i.e. known inhibitors of metalloproteases which may be used *in*

vivo with acceptable toxicity. Further, various prodrugs of Galardin™ would also be interesting candidates.

REMARKS

The specification has been amended to provide a §120 reference and to insert a sequence ID number.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: ______________________
Iver P. Cooper
Reg. No. 28,005

624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms
F:\,P\Plou\Lund1A\ptopreamend1.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the specification:

On page 1, immediately after the title, insert the following new paragraphs:

This is a continuation of Serial No. 09/319,464 filed August 27, 1999, which is the national stage under 35 U.S.C. 371 of PCT/DK97/00555, filed December 8, 1997, and published in English. The latter application claims §119 priority from DK 1402/96, filed December 6, 1996.

The prior application(s) set forth above are hereby incorporated by reference in their entirety.

Paragraph beginning at line 27 of page 25 has been amended as follows:

Preferred examples of the at least one second substance are tissue inhibitor of metalloproteases (such as TIMP-1, TIMP-2, and TIMP-3), alpha-2-macroglobulin, Galardin™, N-[2R-2-(hydroxamidocarbonylmethyl)-4-methylpentanolyl]-L-tryptophan methylamide, batimastat, marimastat, Gl 129471, Gl 168, Gl 173, Gl 179, Gl 184, Cl-A, Cl-B, RP59794, SC-44463, Ro31-4724, CT1746, SCH 47890, a peptide hydroxamate (such as Pro-Leu-Gly-NHOH), LMHKPRCGVPDVGG (SEQ ID NO:1), TNF-α releasing protease inhibitor, Zincov®, Pro-Ileu, phosphoramidon, thiorphan, tiopronin, a tetracycline, N-acetylcysteine, EDTA, or 1,10 phenanthrolene, i.e. known inhibitors of metalloproteases which may be used *in vivo* with acceptable toxicity. Further, various prodrugs of Galardin™ would also be interesting candidates.